Dilated Cardiomyopathy (DCM)

What Is DCM?

Dilated cardiomyopathy (DCM) is a disease of the heart muscle characterized by enlargement (dilation) of one or both ventricles and systolic dysfunction. The ventricle walls become thin and weak, reducing the hearts ability to pump blood effectively, which can lead to heart failure, arrhythmias, and thromboembolic events.

Epidemiology

DCM is one of the most common forms of cardiomyopathy, accounting for roughly 50% of all cases. It affects both sexes equally and can appear at any age, though a peak incidence is seen in individuals aged 2060 years. In the United States, the prevalence is estimated at 1 in 2,500 adults, with higher rates in certain ethnic groups (e.g., African descent).

Causes & Risk Factors

DCM can be broadly divided into:

• Genetic (familial) DCM >30% of cases are linked to pathogenic mutations in genes encoding sarcomeric, cytoskeletal, or mitochondrial proteins (e.g., TTN, LMNA, MYH7).
• Acquired DCM precipitated by external factors:
  • Alcohol abuse (80g/day for >5years)
  • Chemotherapeutic agents (anthracyclines, trastuzumab)
  • Infections (viral myocarditis, especially coxsackievirus B)
  • Toxic exposures (cocaine, heavy metals)
  • Endocrine disorders (thyrotoxicosis, diabetes, adrenal insufficiency)
  • Metabolic diseases (hemochromatosis, Fabry disease)
  • Autoimmune conditions (systemic lupus erythematosus, sarcoidosis)
• Peripartum cardiomyopathy a form of DCM presenting in the last month of pregnancy or within five months postpartum.

Additional risk modifiers include a family history of sudden cardiac death, highintensity endurance training, and certain mitochondrial DNA abnormalities.

Pathophysiology

Key mechanisms driving ventricular dilation and systolic failure include:

1. Myocyte injury and loss necrosis, apoptosis, or impaired autophagy reduce contractile mass.
2. Extracellular matrix remodeling excessive fibrosis stiffens the myocardium and disrupts electrical conduction.
3. Neurohormonal activation chronic elevation of catecholamines, reninangiotensinaldosterone system (RAAS), and natriuretic peptides leads to maladaptive hypertrophy and vasoconstriction.
4. Impaired calcium handling altered sarcoplasmic reticulum function diminishes contractility.

These changes culminate in reduced ejection fraction (typically <40%), increased enddiastolic volume, and a propensity for ventricular arrhythmias.

Clinical Presentation

Symptoms may develop insidiously or present abruptly, depending on the underlying trigger.

Common signs & symptoms

• Dyspnea on exertion or at rest
• Fatigue and reduced exercise tolerance
• Peripheral edema (ankles, sacrum)
• Orthopnea and paroxysmal nocturnal dyspnea
• Palpitations or documented arrhythmias
• Chest discomfort (often nonischemic)

Physical findings

• Elevated jugular venous pressure
• Third heart sound (S3) hallmark of volume overload
• Diffuse apical impulse displaced laterally
• Holosystolic murmur of functional mitral regurgitation
• Signs of low perfusion in advanced stages (cool extremities, oliguria)

Diagnosis

Diagnosis rests on a combination of clinical assessment, imaging, laboratory testing, and sometimes genetic analysis.

Imaging

• Echocardiography firstline; demonstrates enlarged left ventricle (LV enddiastolic diameter >55mm in adults) with reduced EF.
• Cardiac MRI superior for tissue characterization, fibrosis quantification (late gadolinium enhancement), and precise volumetrics.
• Chest Xray may show cardiomegaly and pulmonary congestion.

Electrocardiogram

Nonspecific abnormalities are common: sinus tachycardia, left bundlebranch block, QRS prolongation, or atrial fibrillation.

Laboratory markers

• Elevated Btype natriuretic peptide (BNP) or NTproBNP correlates with heartfailure severity.
• Cardiac troponin may be modestly raised, especially in active myocarditis.
• Screen for metabolic/toxic etiologies (iron studies, thyroid panel, liver function, viral serologies).

Genetic testing

Recommended for patients with a family history of cardiomyopathy or sudden cardiac death, and increasingly for sporadic cases when a clear etiology is not identified.

Diagnostic criteria

According to the 2022 ESC guidelines, DCM is defined by:

• LV or biventricular dilation (indexed LV enddiastolic volume >102mL/m) and
• Reduced systolic function (LVEF <45%) in the absence of abnormal loading conditions (e.g., hypertension, valvular disease) or coronary artery disease sufficient to explain the dysfunction.

Management

Therapeutic goals are to improve symptoms, halt remodeling, reduce mortality, and prevent sudden cardiac death.

Pharmacologic therapy

• ACE inhibitors or ARBs firstline; reduce afterload and attenuate remodeling.
• Betablockers (carvedilol, metoprolol succinate) improve survival and LVEF.
• Mineralocorticoid receptor antagonists (spironolactone, eplerenone) lower hospitalization risk.
• ARNI (sacubitril/valsartan) considered when symptoms persist despite optimal ACEI/ARB/BB therapy.
• SGLT2 inhibitors (dapagliflozin, empagliflozin) now guidelinerecommended for HFrEF irrespective of diabetic status.
• Diuretics for volume overload; judicious use to avoid renal dysfunction.

Device therapy

• Implantable cardioverterdefibrillator (ICD) indicated for primary prevention in patients with LVEF 35% after 3months of optimal medical therapy, or secondary prevention after ventricular arrhythmia.
• Cardiac resynchronization therapy (CRT) beneficial for patients with LVEF 35% and QRS duration 130ms, especially with left bundlebranch block.

Advanced therapies

• Left ventricular assist device (LVAD) as bridgetotransplant or destination therapy.
• Heart transplantation for endstage disease not amenable to LVAD.

Lifestyle and supportive measures

• Salt restriction (2g sodium/day) and fluid limitation as needed.
• Regular, moderateintensity aerobic exercise under supervision.
• Alcohol cessation, avoidance of cardiotoxic drugs, and vaccination (influenza, pneumococcal) to reduce extra cardiac stress.
• Genetic counseling for affected families.

Prognosis & Followup

Prognosis varies widely. Factors associated with poorer outcomes include:

• Persistent LVEF <30% after 6months of therapy
• Presence of sustained ventricular arrhythmias
• Significant myocardial fibrosis on MRI
• Genetic mutations in LMNA or desmin (higher risk of sudden death)
• Advanced NYHA class (IIIIV) at presentation

Regular followup (every 36months) with echocardiography, biomarker assessment, and device interrogation (if applicable) is recommended.

Current Research & Future Directions

Active areas of investigation include:

• Geneediting therapies (CRISPR/Cas9) targeting pathogenic variants in TTN and LMNA.
• RNAbased treatments such as antisense oligonucleotides for mutant transcript suppression.
• Novel smallmolecule modulators of myocardial metabolism (e.g., trimetazidine, ranolazine).
• Expanded use of SGLT2 inhibitors and GLP1 receptor agonists in nondiabetic heartfailure populations.
• Machinelearning algorithms for risk stratification using multimodal imaging and genomic data.

Clinical trials such as GALACTIC (gene therapy for DCM) and METRIC (metabolic modulation) are expected to shape future standards of care.